Evidence map›Paper›PMID 23755143›Full record

ArticlePloS one2013

Trends in the population prevalence of people who inject drugs in US metropolitan areas 1992-2007.

Barbara Tempalski, Enrique R Pouget, Charles M Cleland, Joanne E Brady, Hannah L F Cooper, H Irene Hall, Amy Lansky, Brooke S West, Samuel R Friedman

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 95 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
95citing papers in PubMed, 3 pooled it
8.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

95 citing papers in PubMed, 3 syntheses or guidelines pooled it, 146 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Barriers and Facilitators of Hepatitis C Care in Persons Coinfected with Human Immunodeficiency Virus.International journal of environmental research and public health · 2022
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Observational

35 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 1 country.

Barbara TempalskiInstitute for AIDS Research, National Development and Research Institutes, Inc.-NDRI, New York, New York, United States of America. tempalski@ndri.org
Enrique R Pouget
Charles M Cleland
Joanne E Brady
Hannah L F Cooper
H Irene Hall
Amy Lansky
Brooke S West
Samuel R Friedman
National Development and Research Institutes · USCenters for Disease Control and Prevention · USColumbia University · USEmory University · USJohns Hopkins University · USNational Center for HIV/AIDS Viral Hepatitis STD and TB Prevention · USNew York University · US

Funding

COMMUNITY VULNERABILITY AND RESPONSES TO IDU-RELATED HIVR01DA013336 · NIDA · NATIONAL DEVELOPMENT &RES INSTITUTES · PI COOPER, HANNAH LF, FRIEDMAN, SAMUEL R · 2000 to 2013
$7.6M
NIDA NIH HHS R01 DA013336NIDA NIH HHS R01 DA13336
6 · The paper itself

Abstract

backgroundPeople who inject drugs (PWID) have increased risk of morbidity and mortality. We update and present estimates and trends of the prevalence of current PWID and PWID subpopulations in 96 US metropolitan statistical areas (MSAs) for 1992-2007. Current estimates of PWID and PWID subpopulations will help target services and help to understand long-term health trends among PWID populations. METHODOLOGY: We calculated the number of PWID in the US annually from 1992-2007 and apportioned estimates to MSAs using multiplier methods. We used four types of data indicating drug injection to allocate national annual totals to MSAs, creating four distinct series of component estimates of PWID in each MSA and year. The four component estimates are averaged to create the best estimate of PWID for each MSA and year. We estimated PWID prevalence rates for three subpopulations defined by gender, age, and race/ethnicity. We evaluated trends using multi-level polynomial models.

resultsPWID per 10,000 persons aged 15-64 years varied across MSAs from 31 to 345 in 1992 (median 104.4) to 34 to 324 in 2007 (median 91.5). Trend analysis indicates that this rate declined during the early period and then was relatively stable in 2002-2007. Overall prevalence rates for non-Hispanic black PWID increased in 2005 as compared to other racial/ethnic groups. Hispanic prevalence, in contrast, declined across time. Importantly, results show a worrisome trend in young PWID prevalence since HAART was initiated--the mean prevalence was 90 to 100 per 10,000 youth in 1992-1996, but increased to >120 PWID per 10,000 youth in 2006-2007.

conclusionsOverall, PWID rates remained constant since 2002, but increased for two subpopulations: non-Hispanic black PWID and young PWID. Estimates of PWID are important for planning and evaluating public health programs to reduce harm among PWID and for understanding related trends in social and health outcomes.

Indexed as

AdolescentAdultFemaleHumansMaleMiddle AgedModels, StatisticalPrevalenceReproducibility of ResultsSubstance Abuse, IntravenousUnited StatesUrban PopulationYoung Adult

Identifiers

PMID23755143
PMCPMC3673953
OpenAlexW2022432897

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.